DEF: ResMed FY26: Strong Growth, Strategic Acquisitions, and Shareholder Returns

ResMed reports robust fiscal year 2026 results with 8% revenue growth, 17% EPS increase, and over $1.6 billion in free cash flow, alongside strategic acquisitions and significant capital returns to shareholders.

Summary

• ResMed delivered strong financial and operational results for fiscal year 2026, with revenue growing 8% in constant currency and non-GAAP diluted EPS increasing by 17%.
• The company generated over $1.6 billion in free cash flow and returned more than $1 billion to stockholders through dividends and share repurchases, a 72% increase from the prior year.
• Key strategic moves included the acquisition of Noctrix Health for $340 million to expand into Restless Legs Syndrome (RLS) treatment and the divestiture of the MatrixCare business.
• ResMed plans to return over $1.85 billion to stockholders in fiscal year 2027, including an accelerated share repurchase (ASR) agreement of approximately $1.5 billion.
• The company announced a leadership transition with Carol Burt becoming Lead Director on November 15, 2026, succeeding Ron Taylor who is retiring after over 21 years of service.
• A management transition also occurred with Aaron Bloomer appointed as the new Chief Financial Officer, succeeding Brett Sandercock.
• The annual meeting of stockholders is scheduled for November 18, 2026 (US Time) / November 19, 2026 (Australian Time), with proposals including director elections, ratification of auditors, and advisory approval of executive compensation.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive filing, reflecting strong financial performance and strategic growth initiatives, balanced by ongoing market dynamics.

Positives

• Revenue grew 8% in constant currency and 10% reported in fiscal year 2026.
• Non-GAAP diluted EPS grew 17% in fiscal year 2026.
• Generated over $1.6 billion in free cash flow in fiscal year 2026.
• Returned over $1 billion to stockholders in fiscal year 2026, a 72% increase from the prior year.
• Acquisition of Noctrix Health for $340 million expands into the RLS market.
• Announced plans to return over $1.85 billion to stockholders in fiscal year 2027, including a $1.5 billion ASR.
• Launched new products like AirCurve 11 ST/ST-A, AirTouch fabric masks, and Smart Comfort AI-enabled device.
• Strong cash generation provides flexibility for investments and capital returns.

Negatives

• The stock price performance in fiscal year 2026 eroded stockholder value, with the stock price decreasing from $258.00 to $194.88.
• Performance-based awards for fiscal years 2025 and 2026 would result in zero payouts if measured at the June 30, 2026 stock price.
• The CEO's compensation actually paid for fiscal year 2026 was negative $6.8 million due to adjustments for compensation actually paid.
• The company experienced a decline in stock price during fiscal year 2026, impacting the potential payout of certain equity awards.

Risks

• The company faces global macroeconomic and geopolitical uncertainty.
• The introduction of new weight-loss medications presents both uncertainty and opportunity for the sleep apnea market.
• The company's stock price performance in fiscal year 2026 has reduced the likelihood of payouts for certain performance-based awards.
• The company is subject to risks and uncertainties that could cause actual results to differ materially from forward-looking statements.

Future Outlook

ResMed is focused on enhancing the core business, transforming the core business, and building the future in fiscal year 2027, continuing to invest in innovation, execute with discipline, and invest cash flow to create long-term value for stockholders.

Management Comments

• "At the heart of my message to you is what Resmed truly is: an innovation machine."
• "Our AI-powered digital health capabilities are helping us create more personalized experiences for patients and more efficient workflows for healthcare providers."
• "Resmed is well positioned as the leader in sleep health, at the intersection of these trends."
• "We will continue to invest in innovation, to execute with discipline, and to invest our cash flow to create long-term value for stockholders."
• "Executing today. Building for tomorrow."

Industry Context

StockSavvy.ai notes that ResMed's focus on AI-powered digital health, connected devices, and home healthcare aligns with broader industry trends towards personalized medicine and remote patient monitoring. The acquisition of Noctrix Health and divestiture of MatrixCare demonstrate a strategic sharpening of their portfolio within the sleep and respiratory care space.

Comparison to Industry Standards

• ResMed's revenue growth of 8% in constant currency for FY26 is strong, though specific industry benchmarks for the medical device sector can vary widely based on sub-segment and market conditions.
• The non-GAAP diluted EPS growth of 17% indicates efficient operations and profitability, a positive sign compared to many companies in the healthcare technology sector.
• The company's free cash flow generation of over $1.6 billion is substantial and positions it well for reinvestment and shareholder returns, exceeding many peers in terms of cash conversion.
• The planned capital return of over $1.85 billion in FY27, including a significant ASR, demonstrates a commitment to shareholder value that is aggressive and potentially higher than many competitors of similar size.
• The company's focus on AI and digital health aligns with industry leaders like Philips and Medtronic, who are also investing heavily in these areas to enhance patient outcomes and operational efficiency.

Management Changes

Corporate Governance

Related Party Transactions

• Compensation for Michael Farrell (CEO and Chairman) and Peter Farrell (Founder, Chairman Emeritus) is set in accordance with the related party transaction policy, with independent board approval processes in place for each.
• Michael Farrell is the son of Peter Farrell; their compensation arrangements are subject to specific board approval processes to avoid conflicts of interest.

Stakeholder Impact

• Shareholders: Expected to benefit from strong financial performance, increased capital returns ($1.85 billion planned for FY27), and strategic growth initiatives.
• Employees: The company highlights its commitment to employee well-being and provides comprehensive health and safety programs.
• Healthcare Providers: AI-powered digital health solutions aim to create more efficient workflows.
• Patients: Continued innovation in sleep and breathing health technologies aims to improve quality of life.

Next Steps

• Hold the Annual Meeting of Stockholders on November 18, 2026 (US Time) / November 19, 2026 (Australian Time).
• Elect ten nominees as directors.
• Ratify the selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm for fiscal year ending June 30, 2027.
• Approve, on an advisory basis, the compensation paid to named executive officers.
• Continue to invest in innovation, execute with discipline, and invest cash flow to create long-term value for stockholders in fiscal year 2027.

Key Dates

Recommendation

While ResMed demonstrates strong financial performance and strategic execution, the recent stock price decline and the impact on performance-based compensation payouts suggest a period of caution. The company's long-term prospects remain positive, but current market conditions and the erosion of shareholder value warrant a hold rating pending further stock price recovery and clearer visibility on future growth drivers.

Keywords

ResMed, Proxy Statement, Annual Meeting, Executive Compensation, Director Election, Financial Performance, Shareholder Returns, Acquisition